Drug intelligence / Profile preview

KFP-H018

Development stage: Unknown
Lead developer: Nanjing Carephar Pharmaceutical
Modality: Small Molecules
Administration: Oral, Topical

Overview

KFP-H018 is a selective, small-molecule inhibitor of Janus kinase 1 (JAK1) developed by Nanjing Carephar Pharmaceutical (also known as Jiangsu Carephar Pharmaceutical). It is designed to treat autoimmune diseases and potentially cancer by modulating the JAK-STAT signaling pathway, which is central to inflammatory cytokine signaling. Clinical development has included an oral formulation for rheumatoid arthritis and a topical ointment formulation for dermatological conditions, with Phase I trials evaluating safety, tolerability, and pharmacokinetics.

Other names: H018H-018H 018

Targets

JAK1 (Janus kinase 1)

Beyond the preview

Go deeper on KFP-H018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KFP-H018.

Explore the full profile